An effective therapeutic regime for treatment of glioma using oncolytic vaccinia virus expressing IL-21 in combination with immune checkpoint inhibition

Glioblastoma (GBM) is the most common primary malignant tumor in the brain, accounting for 51.4% of all primary brain tumors. GBM has a highly immunosuppressive tumor microenvironment (TME) and, as such, responses to immunotherapeutic strategies are poor. Vaccinia virus (VV) is an oncolytic virus th...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Yijie, Zhang, Zhe, Zhang, Chenglin, Zhang, Na, Wang, Pengju, Chu, Yongchao, Chard Dunmall, Louisa S., Lemoine, Nicholas R., Wang, Yaohe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9233193/
https://www.ncbi.nlm.nih.gov/pubmed/35795092
http://dx.doi.org/10.1016/j.omto.2022.05.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9233193/
https://www.ncbi.nlm.nih.gov/pubmed/35795092
http://dx.doi.org/10.1016/j.omto.2022.05.008

Ejemplares similares